Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5836723 | 0.93 | KMT2A (0.55) | KMT2ALMNAPTGS1PTGS2CYP2C19 | |
| SCHEMBL28026121 | 0.93 | KMT2A (0.55) | KMT2ALMNAPTGS1PTGS2CYP2C19 | |
| SCHEMBL5835964 | 0.89 | KMT2A (0.50) | KMT2ALMNAPTGS1PTGS2CYP2C19 | |
| SCHEMBL7490890 | 0.84 | MMP8 (0.47) | KMT2ALMNACYP2C19MEN1TSHR | |
| SCHEMBL5836538 | 0.84 | LMNA (0.51) | LMNACYP2C19CYP2D6SRC | |
| SCHEMBL16870979 | 0.82 | KMT2A (0.53) | KMT2ALMNAPTGS1PTGS2MEN1 | |
| SCHEMBL6054594 | 0.80 | CYP1A2 (0.51) | KMT2ALMNAPTGS1PTGS2CYP2C19 | |
| SCHEMBL6054595 | 0.80 | CYP1A2 (0.51) | KMT2ALMNAPTGS1PTGS2CYP2C19 | |
| SCHEMBL6248685 | 0.80 | CYP1A2 (0.51) | KMT2ALMNAPTGS1PTGS2CYP2C19 | |
| SCHEMBL6248687 | 0.80 | CYP1A2 (0.51) | KMT2ALMNAPTGS1PTGS2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7005521-B1 | Catalytic compositions and methods for asymmetric allylic alkylation | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2006-02-28 | — | — | US | disclosed |
| US-6747152-B2 | COMPRISES MOLYBDENUM/TUNGSTEN/CHROMIUM COMPLEXES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2004-06-08 | — | — | US | disclosed |
| US-20030191340-A1 | Catalytic compositions and methods for asymmetric allylic alkylation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-10-09 | — | — | US | disclosed |
| EP-1049537-B1 | CATALYTIC COMPOSITIONS AND METHODS FOR ASYMMETRIC ALLYLIC ALKYLATION | UNIV LELAND STANFORD JUNIOR (US) | 2003-08-06 | — | — | EP | disclosed |
| US-6541655-B2 | For use in regioselective and enantioselective alkylations of allylic substrates | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2003-04-01 | — | — | US | disclosed |
| US-20020198383-A1 | Catalytic compositions and methods for asymmetric allylic alkylation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-12-26 | — | — | US | disclosed |
| EP-1049537-A2 | CATALYTIC COMPOSITIONS AND METHODS FOR ASYMMETRIC ALLYLIC ALKYLATION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2000-11-08 | — | — | EP | disclosed |
| US-6130349-A | USING COMPLEX OF MOLYBDENUM, TUNGSTEN OR CHROMIUM WITH 1,1*-BINAPHTHYL SYSTEM CONTAINING HETEROCYCLIC NITROGEN GROUP; ENANTIO- AND REGIOSELECTIVITY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2000-10-10 | — | — | US | disclosed |
| WO-1999032225-A9 | CATALYTIC COMPOSITION BASED ON CHIRAL LIGANDS WITH MOLYBDENUM, TUNGSTEN OR CHROMIUM AND METHOD FOR ASYMMETRIC ALKYLATION OF ALLYLIC SUBSTRATES | UNIV LELAND STANFORD JUNIOR (US) | 1999-09-30 | — | — | WO | disclosed |
| WO-1999032225-A2 | CATALYTIC COMPOSITION BASED ON CHIRAL LIGANDS WITH MOLYBDENUM, TUNGSTEN OR CHROMIUM AND METHOD FOR ASYMMETRIC ALKYLATION OF ALLYLIC SUBSTRATES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198383-A1 | Catalytic compositions and methods for asymmetric allylic alkylation | MPG, UNG, APOBEC3C | KMT2A 1585/4885LMNA 3748/4885PTGS1 4633/4885 |
| US-20030191340-A1 | Catalytic compositions and methods for asymmetric allylic alkylation | MPG, UNG, APOBEC3C | KMT2A 1585/4885LMNA 3748/4885PTGS1 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.